Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET) and ...

Efforts to improve standard treatments have focused on the development of more potent and longer-lasting interferons, including albumin IFN-α and consensus interferons. Another area of active ...

have described previously an oligonucleotide-based inhibitor of TLR7 and TLR9, called immunoregulatory sequence (IRS) 954, which can block B-cell activation and interferon-α production by PDCs.